Fibromyalgianess Glucocorticoid Persistence in RA Patients: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #0120 presented at the #ACR21 annual meeting. https://t.co/9yOM5rSARv https://t.co/Gq2YxbxkmM

• https://bit.ly/3mU8Voe

Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated with remission (per DAS28, SDAI, CDAI) in mod-severe RA patients treated w/ SQ Abatacept: ⭐️Seropositivity ⭐️no prior bMDARD use ⭐️low HAQ-DI ⭐️low BMI Abst#1228 @ACR21 @Rheumnow https://t.co/LRd1HVbm5B

Abst 1661 Scheir & colleagues identified patterns of multimorbidity and association w/ disability in patients w/ early RA - In women: Depression significantly associated w/ disability - In men: HTN & Lung Disease significantly associated w/ disability #ACR21 @RheumNow https://t.co/0qkn1TcvOi

Hair Loss due to Methotrexate from RCTs in RA estimated at 6.9%. It's an understandable source of concern for those taking the medication #ACR21 https://t.co/GymV2RC7jT

French study shows more than 75% of RA/SpA pregnancies resulted in a live-birth, BUT 50% of pts had at least one unfavorable pregnancy outcome! However, miscarriage prevalence lower than in reported literature. Abs 1724 #ACR21 #RheumNow @RheumNow https://t.co/64PspIKPTu https://t.co/LyfHVARAgd

• More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an …

ARIAA Study - Abatacept Reverses ACPA+ Subclinical Arthritis: Dr. Jack Cush discusses abstract #0455, a preclinical RA intervention trial - abatacept or placebo given to at risk individuals (arthralgias, CCP+, MRI+) for 6 months, presented at #ACR21. https://t.co/fz1hPTleMn https://t.co/V4PsPZ0ZwF

• https://bit.ly/3o2XwC2

Glory to GLORIA trial? Low dose prednisone 2mg in active RA>65yrs, N=451 All Standard care. in 2yrs, ~40% drop out- same in each grp Better RA control but NNH 9.5 w steroids, mostly non severe infections. So, prednisone debate in RA continues #ACR21 @RheumNow #ACRBest abst#1678 https://t.co/emOaYSjYAa

Just worthwhile remembering: in terms of TNFi anti-drug immunogenicity in autoimmune disease: RA is top of the pops (although dose spacing is worse) data from NOR-DRUM A, TDM in infliximab #ACR21 ABST1525 @RheumNow https://t.co/wfcA72wcLP https://t.co/mHppH6qYdY

• https://meet.acrconvergence.org/meetings/virtual/nanQoptmXdF2qGxPi

Pirfenidone in RA-ILD, TRAIL-1 study. Long-awaited. Early termination due to COVID led to under-powering. Slowed decline in FVC, especially in UIP pattern. Seemed to have less adverse events than we see with nintedanib. Abstr#L10 #ACR21 @RheumNow https://t.co/sYRDhG3u4y